Efficacy and Safety of Oral Tofacitinib in the Treatment of Alopecia Areata
Status:
Completed
Trial end date:
2023-08-04
Target enrollment:
Participant gender:
Summary
This clinical trial was conducted at the Dermatology department of Services hospital Lahore.
Patients of extensive and treatment resistant Alopecia areata were enrolled after ethical
approval and informed consent by non-probability consecutive sampling. Inclusion criteria:
Treatment with oral tofacitinib citrate was initiated at 5 mg twice daily for six months.
Scalp hair loss was calculated at 4, 12 and 24 weeks using the validated Severity of Alopecia
Tool (SALT) score, which ranges from 0% to 100%. Regrowth rate: (initial SALT score - final
SALT score)/(initial SALT score) × 100 was noted. Response time (time from initiation of
treatment to any sign of hair regrowth) was noted. DLQI of patients before and after
treatment were noted. Side effects were noted. Pre- and post-treatment photographs were
taken. Patients were followed up for another 6 months to look for relapse.
Data were entered and analyzed using SPSS 20. Means were calculated for quantitative
variables, frequencies for qualitative data. Data were stratified for the role of effect
modifiers.